In 2006, AstraZeneca entered the antibiotic area and developed novel therapy for severely infected patients having high drug resistance.
2006年阿斯利康开始进入抗菌素领域,开发研制新一代的抗菌素以治疗对现有抗菌素高度耐药的重症感染病人。
To guide reasonably antival therapy in clinic and make therapic remedy, it is necessary for HBV-infected patients before or after antiviral therapy to detect HBV YMDD mutations.
HBV感染患者在治疗前后有必要检测是否存在HBV YMDD 变异株感染,为指导临床科学合理用药和制定治疗方案提供依据。
应用推荐